Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Keros Therapeutics has reported Total Non-Current Liabilities for 3 years, with the latest figure at $12.1 million in Q4 2021.

• For the quarter ending Q4 2021, Total Non-Current Liabilities rose 57.66% year-over-year to $12.1 million; the trailing twelve-month figure through Dec 2021 stood at $12.1 million (up 57.66% YoY), and the FY2021 full-year result was $12.1 million, up 57.66% from the prior year.
• Total Non-Current Liabilities for Q4 2021 stood at $12.1 million, up from $11.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $12.1 million in Q4 2021, with the low at $7.4 million in Q3 2020.
• Historically, Total Non-Current Liabilities has averaged $9.4 million across 3 years, with a median of $9.3 million in 2021.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities declined 25.93% — and 2021, when it surged 57.66%.
• Keros Therapeutics' Total Non-Current Liabilities stood at $10.3 million in 2019, then declined by 25.93% to $7.7 million in 2020, then surged by 57.66% to $12.1 million in 2021.
• The last three Total Non-Current Liabilities figures came in at $12.1 million (Q4 2021), $11.5 million (Q3 2021), and $7.8 million (Q2 2021), per Business Quant data.